



(51) **International Patent Classification:**
C07D 307/68 (2006.01) **A61P 35/00** (2006.01)
A61K 31/341 (2006.01)

(21) **International Application Number:**
PCT/US2011/039377

(22) **International Filing Date:**
7 June 2011 (07.06.2011)

(25) **Filing Language:** English

(26) **Publication Language:** English

(30) **Priority Data:**
61/352,308 7 June 2010 (07.06.2010) US

(71) **Applicant (for all designated States except US):**
NOVOMEDIX, LLC [US/US]; 11575 Sorrento Valley Road, Suite 210, San Diego, CA 92121 (US).

(72) **Inventors; and**

(75) **Inventors/Applicants (for US only):** **FUNG, Leah, M.** [US/US]; 12255 Mannix Road, San Diego, CA 92129 (US). **CHAN, Kyle, W., H.** [US/US]; 5132 Greenwillow Lane, San Diego, CA 92130 (US). **SWINDLEHURST, Cathy, A.** [US/US]; 5132 Greenwillow Lane, San Diego, CA 92130 (US).

(74) **Agents:** **RIEGER, Dale, L.** et al.; Jones Day, 222 East 41st Street, New York, NY 10017-6702 (US).

(81) **Designated States (unless otherwise indicated, for every kind of national protection available):** AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States (unless otherwise indicated, for every kind of regional protection available):** ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) **Title:** FURANYL COMPOUNDS AND THE USE THEREOF






Figure 1.



(57) **Abstract:** Provided herein are substituted furanyl compounds of formula (I), pharmaceutical compositions comprising the compounds, methods of their preparation, and methods of their use. The compounds provided herein are useful for the treatment, prevention, and/or amelioration of various disorders, including cancer and proliferative disorders. In one embodiment, the compounds provided herein modulate eIF4E activity. In one embodiment, the compounds provided herein modulate the Hedgehog pathway activity. In one embodiment, the compounds provided herein are used in combination with surgery, radiation therapy, immuno therapy and/or one or more additional anticancer drugs for the treatment, prevention, and/or amelioration of cancer and proliferative disorders.